Lexaria Bioscience Corp. · NASDAQ:LEXX
Lexaria Bioscience — Investor Presentation (November 2017)
16 slides from Lexaria Bioscience's investor presentation, Nov 2, 2017
Slide 1: Lexaria Bioscience Corp. Investor Presentation
Lexaria Bioscience Corp. Investor Presentation LXX:CSE | LXRP:US J Powered by 4 Lexaria November 2017 bs BIOSCIENCE LexariaBioscience.com
Slide 2: Disclaimer
Powered by V Lexaria Disclaimer Saw A) BIOSCIENCE This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forwa
Slide 3: Drug Delivery Platform Innovation
Powered by i=, Drug Delivery Platform Innovation oa A) BIOSCIENCE Lexaria Bioscience has developed a new disruptive drug delivery platform: DehydraTECH™ Patented technology changes the way Active Pharmaceutical Ingredients (“APIs”) enter the body orally: 1) Masks unwanted tastes Eliminates the need
Slide 4: Patent Portfolio
$=. Patent Portfolio gv BIOSCIENCE 19 patent applications filed: In the US and internationally under the Patent Cooperation Treaty (PCT), including national/regional filings covering 44 countries. Patents granted - name a broad range of lipophilic bioactives and food/carrier particles that can be fo
Slide 5: Lexaria Transforming entry into the body
ld Lexaria Transforming entry into the body BIOSCIENCE Lexaria transforms the way Active Pharmaceutical Ingredients (“APIs”) enter the bloodstream through the Gastrointestinal Tract Lexaria’s Patented DehydraTECH™: | attribute | Traditional Delivery | DehydraTECH™Delivery - Lexaria Science 1 Taste B
Slide 6: How does DehydraTECH work?
i How does DehydraTECH™ work? oa A) BIOSCIENCE Process: 1) Combine API and Fatty Acid Oil ¥ aa e.g: THC LCFA: sunflower oil 2) Apply to food/carrier particles aC) INS e.g.: mannitol, gum Arabic, etc, 3) Perform dehydration procedure 1 1 ! 1 1 ! 1 1 1 ! ! 1 1 1 1 1 1 1 ! 1 1 ! I-OH + Hof —> lol ; deh
Slide 7: Commercial Applications
re, Commercial Applications gv BIOSCIENCE Cannabinoids Vitamins NSAIDs Nicotine * Ingestible product * Existing and new * Alternate means to * World's first ingestible formats of all types, ingestible product formulate NSAIDs, nicotine products, + Enhanced palatability, formats, + Higher bioavailabi
Slide 8: Cannabinoids: Plant-to-bloodstream
a Y Lexaria Cannabinoids: Plant-to-bloodstream > BIOSCIENCE 3 prominent ways cannabinoids enter the blood stream: 1) Inhalation (GEM: High bioavailability (est. 30%) * Harmful to Lungs : 2) Sub-lingua! (under tongue) > Medium bioavailability (est. 16%) Foul taste 3) Oral — Gastrointestinal Tract Low
Slide 9: Lab Testing | Scientific Research
Mim, Lab Testing | Scientific Research oat A) BIOSCIENCE In vitro Absorption Study Aug 2015, showed 499% increase in CBD bioabsorption in human intestinal tissues. Human Biomarker Study \ Jan 2016, human subjects, 5-10 X increase in salivary nitric oxide (CBD surrogate) within 15- 30 min. ten Human
Slide 10: Cannabis regulatory environment
y¥ BIOSCIENCE Regulation trend to prohibit / limit smoking: Florida, Pennsylvania, California, numerous US city councils, Canada Regulation trend to limit dosage in edibles: State of Nevada, Jul 1, 2017 Max THC for edibles: 100mg/package and 10mg/serving, State of California, Jan 1, 2018 Max THC for
Slide 11: Business model: royalties & sales
Vicia Business model: royalties & sales yh BIOSCIENCE Out-licensing DehydraTECH™ to third-party partners using high margin royalty model Initial focus on THC / CBD edibles manufacturers: First licensee - cannabis chocolate company located in Colorado with expansion rights, Advanced discussions under
Slide 12: Nicotine: a smoke-free future
Vin Nicotine: a smoke-free future SOZV BIOSCIENCE Regulatory pressure against cigarettes is increasing: FDA to pursue lowering nicotine in cigarettes to non addictive levels (July 2017). Big Tobacco responds: Phillip Morris — pledges $18 to anti-smoking, shuffles management toward smoke-free future
Slide 13: NSAIDs: new pain relief solution
Mi NSAIDs: new pain relief solution = BIOSCIENCE NSAIDs (nonsteroidal anti-inflammatory drugs) are among the most common pain relief medicines in the world Most common are acetylsalicylic acid (ASA) and ibuprofen, Generally a safe and effective treatment method for pain, but associated with a number
Slide 14: Vitamins: alternate delivery methods
SF, Vitamins: alternate delivery methods y¥ BIOSCIENCE Vitamins can be divided into two broad categories Water soluble, Fat soluble (including vitamins A, D, K and E) Fat soluble vitamins are generally harder to absorb in the intestines Food and supplement manufacturers often use synthetic versions
Slide 15: Key executives & advisors
Powered by we Lexaria Key executives & advisors a A) BIOSCIENCE Chris Bunka - Chairman & CEO Serial entrepreneur involved in several private and public companies since the late 1980's. Extensive experience in the capital markets, corporate governance, M&A and finance. John Docherty, M.Sc. - Director
Slide 16: Stock Information and Contact Information
V Lexaria SGV BIOSCIENCE Trading symbol: Shares o/s: Fully diluted: Recent price: Management & Insiders: Recent Financings: Fiscal year-end: Stock Information CSE:LXX, OTCQB:LXRP 68m 79m cS$0.47 / USS$0.38 14m (21%) Brokered financing | USS1.7M @ USS$0.42/unit (april), August 31 Contact Information
Lexaria Bioscience — Investor Presentation (November 2017) on 6ix